Bolt Biotherapeutics, Inc. Stock Price, News & Analysis

Bolt Biotherapeutics (BOLT) has entered into a collaboration with Innovent Biologics to develop three new anti-cancer therapeutic immune-stimulating antibody conjugates (ISACs). Innovent will pay an upfront fee of $5 million and handle development costs through clinical proof of concept. The partnership allows Innovent exclusive rights in Greater China while Bolt retains rights elsewhere. Potential future equity investments could reach $10 million, alongside milestone payments and royalties based on product development and commercialization.

Bolt Biotherapeutics (NASDAQ: BOLT) announced promising updates in its Phase 1/2 trial for BDC-1001 targeting HER2-expressing solid tumors, with data expected in 2H 2021. The company reported a robust cash position of $310.9 million as of June 30, 2021, which will fund operations through 2023. A collaboration with Genmab aims to develop bispecific ISACs for cancer treatment, securing an upfront payment of $10 million and potential future earnings of $285 million per program. R&D expenses rose to $19.7 million, while G&A expenses increased to $4.1 million in Q2 2021.

Bolt Biotherapeutics (BOLT) has showcased positive preliminary data from a Phase 1/2 clinical trial of BDC-1001 at the ASCO Annual Meeting. As of January 29, 2021, 20 patients treated with the HER2-targeting ISAC displayed tolerable safety with no serious adverse effects. Clinical activity included stable disease and a confirmed partial response in some patients. The trial aims to enroll up to 390 patients, with further results expected in H2 2021, including monotherapy and combination treatments.

Genmab and Bolt Biotherapeutics announced a collaboration aimed at developing novel cancer therapies using Genmab's antibody technologies and Bolt's immune-stimulating antibody conjugate (ISAC) platform. The partnership includes an upfront payment of USD 10 million and an equity investment of USD 15 million from Genmab. They plan to develop multiple bispecific ISAC candidates, with Genmab holding options to commercialize up to three candidates. Total potential milestone payments could reach USD 285 million per candidate, depending on successful development and commercialization.

Bolt Biotherapeutics reported a strong cash position of $302.9 million as of March 31, 2021, which is anticipated to support operations into 2023. The company successfully raised $264.5 million from its upsized IPO in February 2021. Bolt is progressing on its lead program, BDC-1001, with a Phase 1/2 trial expected to provide updates in the second half of 2021. In Q1 2021, R&D expenses rose to $14.1 million, while the loss from operations increased to $24.5 million. The company's strategic initiatives aim to enhance shareholder value through ongoing clinical trials and pipeline advancements.

Bolt Biotherapeutics (Nasdaq: BOLT) announced the ongoing Phase 1/2 study of its lead clinical candidate, BDC-1001, at the AACR Annual Meeting 2021. This first-in-class HER2-targeting immune-stimulating antibody conjugate is designed to convert cold tumors into hot ones, enhancing anti-tumor immune response. The study involves evaluating safety and efficacy in up to 390 patients with HER2-expressing tumors. Initial results showed promising signs of clinical activity and acceptable safety with no dose-limiting toxicities reported.

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company, is set to present at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 10:15 AM ET. CEO Randall C. Schatzman, Ph.D., will provide an overview of the company. Bolt is pioneering immuno-oncology agents, specifically Boltbody™ Immune-stimulating Antibody Conjugates (ISACs), which aim to convert ‘cold’ tumors to ‘hot’ tumors. Their lead candidate, BDC-1001, targets HER2-expressing solid tumors and is currently in phase 1/2 clinical testing.

Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) reported strong fundraising outcomes, raising $358 million through an upsized IPO and Series C financing. The company announced positive preliminary results from its Phase 1/2 trial of BDC-1001, targeting HER2-expressing solid tumors, showing clinical activity in 20 treated patients. R&D expenses increased to $40.4 million in 2020 from $26 million in 2019. Despite a reported loss from operations of $49.2 million for the year, the company maintains a strong cash position to fund operations into 2023.

Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) has successfully closed its initial public offering, selling 13,225,000 shares at $20.00 each. This includes the full exercise of the underwriters' option for an additional 1,725,000 shares. The company specializes in developing immune-oncology therapies, particularly its lead candidate BDC-1001, aimed at HER2-expressing solid tumors. The offering was managed by Morgan Stanley, SVB Leerink, Stifel, and Guggenheim Securities.